Safety and performance of the EverProTM everolimus-eluting coronary stent system with biodegradable polymer in a real-world scenario

doi:10.4330/wjc.v12.i12.615

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 12

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6827)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-2) series.

Item

Count

PDF

333

WORD

152

HTML

2707

Figures (1-2)

387

Tables (1-2)

343

Sum=3922

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

314

Download

669

Sum=983

Publishing Process of This Article

Item

Count

Browse

594

Download

1328

Sum=1922

Dec 26, 2020 (publication date) through Mar 2, 2025

Times Cited of This Article

Times Cited (2)

Journal Information of This Article

Publication Name

World Journal of Cardiology

ISSN

1949-8462

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Cardiol. Dec 26, 2020; 12(12): 615-625
Published online Dec 26, 2020. doi: 10.4330/wjc.v12.i12.615

Table 1 Baseline demographics and clinical characteristics

Characteristics	n = 77
Age (mean ± SD), yr	55 ± 11.8
Men, n (%)	59 (76.6)
Medical history, n (%)
Hypertension	37 (48.1)
Diabetes	15 (19.48)
Smoking	24 (31.2)
Consumption of alcohol	9 (11.7)
Stroke	2 (2.6)
Previous coronary intervention	4 (5.2)
Previous myocardial infarction	34 (44.2)
Cardiac status, n (%)
Stable angina	30 (39)
Unstable angina	13 (16.9)
STEMI	26 (33.8)
NSTEMI	8 (10.4)
Coronary angiogram finding, n (%)
Single-vessel disease	61 (79.2)
Double-vessel disease	16 (20.8)
Triple-vessel disease	0 (0.0)
Heart rate (mean ± SD), bpm	81.26 ± 12.08
Systolic blood pressure (mean ± SD), mmHg	134.91 ± 27.51
Diastolic blood pressure (mean ± SD), mmHg	83.19 ± 13.57
Serum creatinine (mean ± SD), mg/dL	1.13 ± 0.23
LVEF (mean ± SD), %	46.38 ± 8.19

LVEF: Left ventricular ejection fraction; NSTEMI: Non-stent thrombosis segment elevation myocardial infarction; SD: Standard deviation; STEMI: Stent thrombosis segment elevation myocardial infarction; bpm: Beats per minute.

Citation: Trimukhe R, Vani P, Patel A, Salgotra V. Safety and performance of the EverPro^TMeverolimus-eluting coronary stent system with biodegradable polymer in a real-world scenario. World J Cardiol 2020; 12(12): 615-625
URL: https://www.wjgnet.com/1949-8462/full/v12/i12/615.htm
DOI: https://dx.doi.org/10.4330/wjc.v12.i12.615